Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Detalles Bibliográficos
Autores principales: Mansell, Kerry, Bhimji, Hishaam, Eurich, Dean, Mansell, Holly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918652/
https://www.ncbi.nlm.nih.gov/pubmed/31849317
http://dx.doi.org/10.1186/s12913-019-4829-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918652/
https://www.ncbi.nlm.nih.gov/pubmed/31849317
http://dx.doi.org/10.1186/s12913-019-4829-z

Ejemplares similares